New hope for advanced esophageal cancer: combo therapy trial launches
NCT ID NCT06780111
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 4 times
Summary
This study tests new drug combinations (including an antibody-drug conjugate) with the immunotherapy pembrolizumab, with or without chemotherapy, for people with advanced esophageal cancer that cannot be removed by surgery or has spread. About 298 participants will join to see if the treatments are safe and help shrink tumors. The goal is to find better options for this hard-to-treat cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Aichi Cancer Center ( Site 9702)
RECRUITINGNagoya, Aichi-ken, 464-8681, Japan
-
Asan Medical Center ( Site 9901)
RECRUITINGSeoul, 05505, South Korea
-
Beijing Cancer Hospital ( Site 9500)
RECRUITINGBeijing, Beijing Municipality, 130021, China
-
Bradford Hill Norte ( Site 1405)
RECRUITINGAntofagasta, 1263521, Chile
-
Bradfordhill ( Site 1401)
RECRUITINGSantiago, Region M. de Santiago, 8420383, Chile
-
C.H.R.U. de Brest - Hopital Cavale Blanche ( Site 9104)
RECRUITINGBrest, Finistere, 29609, France
-
CHU Lille - Institut Coeur Poumon ( Site 9100)
RECRUITINGLille, Nord, 59037, France
-
Centro de Oncología de Precisión ( Site 1402)
RECRUITINGSantiago, Region M. de Santiago, 7560908, Chile
-
Chang Gung Memorial Hospital - Linkou Branch ( Site 1006)
RECRUITINGTaoyuan, 33305, Taiwan
-
China Medical University Hospital ( Site 1007)
RECRUITINGTaichung, 40707, Taiwan
-
Clínica Puerto Montt ( Site 1406)
RECRUITINGPort Montt, Los Lagos Region, 5500243, Chile
-
Clínica UC San Carlos de Apoquindo ( Site 1403)
RECRUITINGSantiago, Region M. de Santiago, 7620002, Chile
-
FALP ( Site 1400)
RECRUITINGSantiago, Region M. de Santiago, 7500921, Chile
-
Haematologisch-Onkologische Praxis Eppendorf Facharztzentrum Eppendorf - Hope ( Site 1807)
RECRUITINGHamburg, 20249, Germany
-
Henan Cancer Hospital ( Site 9509)
RECRUITINGZhengzhou, Henan, 450008, China
-
Hopitaux Universitaires de Geneve HUG. ( Site 1701)
RECRUITINGGeneva, 1211, Switzerland
-
Hospital Nossa Senhora da Conceicao ( Site 1300)
RECRUITINGPorto Alegre, Rio Grande do Sul, 91010-004, Brazil
-
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1302)
RECRUITINGSão Paulo, 01246-000, Brazil
-
Istituto Oncologico Veneto IRCCS ( Site 9202)
RECRUITINGPadova, Veneto, 35128, Italy
-
Kantonsspital Graubuenden ( Site 1700)
RECRUITINGChur, Kanton Graubünden, 7000, Switzerland
-
Kaohsiung Chang Gung Memorial Hospital ( Site 1003)
RECRUITINGKaohsiung City, 83301, Taiwan
-
Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 1009)
RECRUITINGKaoshiung, Kaohsiung, 807, Taiwan
-
Liga Norte Riograndense Contra o Cancer ( Site 1301)
RECRUITINGNatal, Rio Grande do Norte, 59062-000, Brazil
-
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 9000)
RECRUITINGBrno, Brno-mesto, 656 53, Czechia
-
National Cancer Center ( Site 9902)
RECRUITINGGoyang-si, Kyonggi-do, 10408, South Korea
-
National Cancer Center Hospital ( Site 9700)
RECRUITINGChūō, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East ( Site 9701)
RECRUITINGKashiwa, Chiba, 277-8577, Japan
-
National Cheng Kung University Hospital ( Site 1001)
RECRUITINGTainan, 704, Taiwan
-
National Taiwan University Hospital ( Site 1000)
RECRUITINGTaipei, 100225, Taiwan
-
National University Hospital ( Site 9800)
RECRUITINGSingapore, Central Singapore, 119074, Singapore
-
Oslo Universitetssykehus Radiumhospitalet ( Site 1501)
RECRUITINGOslo, 0379, Norway
-
Ospedale San Raffaele-Oncologia Medica ( Site 9201)
RECRUITINGMilan, Lombardy, 20132, Italy
-
Pitie Salpetriere University Hospital ( Site 9102)
RECRUITINGParis, 75013, France
-
Ramathibodi Hospital ( Site 1103)
RECRUITINGRatchathewi, Bangkok, 10400, Thailand
-
Samsung Medical Center ( Site 9900)
RECRUITINGSeoul, 06351, South Korea
-
Songklanagarind hospital ( Site 1101)
RECRUITINGHat Yai, Changwat Songkhla, 90110, Thailand
-
Taipei Veterans General Hospital ( Site 1005)
RECRUITINGTaipei, 11217, Taiwan
-
The First Affiliated Hospital of Nanchang University ( Site 9505)
RECRUITINGNanchang, Jiangxi, 330006, China
-
The First Affiliated Hospital of Xiamen University ( Site 9503)
RECRUITINGXiamen, Fujian, 361003, China
-
The Second Affiliated Hospital of Anhui Medical University ( Site 9511)
RECRUITINGHefei, Anhui, 230601, China
-
UPMC Hillman Cancer Center ( Site 1904)
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
Universitaetsklinikum Duesseldorf ( Site 1808)
RECRUITINGDüsseldorf, North Rhine-Westphalia, 40225, Germany
-
Universitätsklinikum Carl Gustav Carus - Medical Oncology ( Site 1806)
RECRUITINGDresden, Saxony, 01307, Germany
-
Xuzhou Central Hospital ( Site 9512)
RECRUITINGXuzhou, Jiangsu, 221000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads